Weatherden

Patients

A half-day symposium – titled Women’s Health: From Intractable to Investable – was held in London on 11th June, organised by Weatherden.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.